INTRODUCTION
Protein phosphorylation regulates a diverse range of cellular processes. A rapidly growing area of interest in the study of protein phosphorylation is the regulation of cellular growth through phosphorylation of key nuclear proteins. The growing list of such nuclear 'effector' proteins includes proto-oncogene products that function as transcription factors as well as tumour suppressor proteins that may be involved in regulating the onset of DNA replication. Regulation of the activities of these proteins can occur through phosphorylation and dephosphorylation mechanisms that in turn respond to the timing mechanism of the cell cycle, or directly to extracellular signals transduced to the nucleus by 'cascade events'. In addition, some viral proteins that stimulate cellular growth are also regulated by phosphorylation or are able to influence the phosphorylation of proteins central to growth regulation ( Fig. 1) .
This Review examines the phosphorylation of a selected number of nuclear proteins that are involved in the control of cellular growth and that illustrate the extent ofpresent knowledge about nuclear signal transduction. These proteins include the transcription factors, CREB, Jun, Fos, NFKB, Myc and Myb, four of which are the products of proto-oncogenes (Jun, Fos Myc and Myb); two tumour suppressor proteins, p53 and the product of the retinoblastoma susceptibility gene (pRB); and the simian virus 40 (SV40) large tumour antigen (T antigen) which is a multifunctional viral protein involved in DNA replication, transcription and cellular transformation. The effects of phosphorylation on biochemical activity and biological function are discussed, together with the protein kinases and phosphatases involved and their response to a valiety of growth factors and tumour promoters. Interestingly, several of these proteins are phosphorylated by the same protein kinases, suggesting that signals may co-ordinately target these key proteins. In some cases, there is a relationship between nuclear phosphorylation events and cellular transformation in which oncogene products play a role. Each protein is multiply phosphorylated and in some cases phosphorylation at a particular site occurs in response to different signals. Finally, some proteins respond directly to external stimuli while others are phosphorylated temporally in response to the timing mechanism of the cell cycle. Taken together, these examples give an overview of the role of phosphorylation of nuclear proteins in growth control.
CREB
The cyclic AMP (cAMP) responsive element binding protein (CREB) mediates the stimulation of gene expression in response to factors that elevate intracellular cAMP levels (for detailed reviews see Montminy et al., 1990 Montminy et al., , 1991 Bohmann, 1990) . The identification of this protein established a direct link between the hormonal stimulation of cells and the modulation of transcriptional activity. CREB has also proved to be an excellent example of a nuclear protein which mediates 'cross-talk' between different signal transducing pathways.
CREB was discovered (Montminy & Bilezikjian, 1987; Yamamoto et al., 1988) through its interaction with the cAMP responsive element, a short palindromic core sequence (5'-TGACGTCA-3'; Montminy et al., 1986; Comb et al., 1986; Short et al., 1986) which is present in cAMP-inducible promotors and which mediates cAMP-dependent stimulation of transcription (several of these promoters are described by Montminy et al., 1991) . CREB is a dimeric protein of subunit Mr 43000 (Hoeffier et al., 1988; which contains three major structural elements: a DNA-binding domain rich in basic amino acids, a leucine zipper responsible for dimerization and a Signals initiated at the cell membrane are transduced (via second messengers, kinases and/or phosphatases) to the nucleus. There, they converge on key nuclear proteins which are important for regulating growth. Other signals (e.g. arising from the timing mechanism of the cell cycle) may modulate protein phosphorylation. In addition, oncogene products may have potent effects on the phosphorylation of nuclear proteins. The symbol of a circle with the letter P in the centre (in this and in all other figures) signifies a phosphorylation site.
highly acidic transactivation region (amino acids 88-160) which contains a cluster of potential phosphorylation sites [for cyclic AMP-dependent protein kinase (PKA), protein kinase C (PKC), glycogen synthase kinase 3 (GSK3), casein kinase I (CKI) and casein kinase II (CKII); see Fig. 2 ]. These phosphorylation sites lie within a subdomain termed the P-box which is important for the induction of gene expression. CREB is now known to be identical to activating transcription factor 47 (ATF47) which is a member of a larger family of transcription factors (Hurst et al., 1990) . It is also closely related to the AP-l family of transcription factors and its target sequence differs from the consensus AP-1 motif [also known as the TPA-responsive element (TRE)] in only one base (Hoeffler et al., 1988; . CREB is phosphorylated by cAMP-dependent protein kinase (PKA) in vitro at Ser-133 which lies within the P-box region of the transactivation domain. This residue is also phosphorylated in vivo in response to forskolin, an activator of adenylate cyclase . Phosphorylation by PKA has no effect on the ability of CREB to bind to the CRE, but enhances transcription efficacy in vitro by 20-fold . Mutational studies have shown that CREB is unable to activate transcription in vivo when Ser-133 is replaced by non-phosphorylatable amino acids Lee et al., 1990) . Based on these findings, a model was proposed for the cAMP-dependent induction of gene expression. Following hormonal stimulation, increased cAMP levels promote dissociation of PKA holoenzyme. The active catalytic subunit is then transported to the nucleus (Nigg et al., 1985) where it phosphorylates CREB at Ser-133. This phosphorylation event is thought to activate CREB by inducing a conformational change in the protein which allows the negatively charged transactivation domain to interact with its target protein, the TATA-binding factor TFIID (Horikoshi et al., 1988) .
Two other regions within the transactivation domain are now known to be important for the stimulation of transcription by CREB. The first of these is the a peptide which comprises amino acids 88-101. This a-helical region is encoded by an alternative exon and is absent from ACREB (alternatively designated CREB-327), a lower activity form of CREB. The a peptide interacts co-operatively with the PKA phosphorylation site and is important for maximal cAMPdependent induction . The second subdomain, which is required for full transcriptional activity, lies within the P-box and is termed the PDE1 region. This domain was identified by deletion mapping and comprises amino acids 106-124 in the full-length CREB protein see Fig. 2 ). Multiple phosphorylation of PDE1 in vivo occurs independently of phosphorylation at Ser-133. CKII will phosphorylate all five serine residues within this peptide in vitro , although the spacing of the five serine residues would also suggest that this region is a substrate for processive phosphorylation by CKI. It is not known which enzyme phosphorylates these residues physiologically, nor what effect phosphorylation of this region has on CREB activity. CKII is also able to phosphorylate the PDE3 region (amino acids 138-148), but loss of these residues does not appear to influence cAMP inducibility . [CKII is a ubiquitous cyclic nucleotide-independent protein kinase so called because conventionally it has been assayed using casein as its substrate (for reviews see Pinna, 1990; Meisner & Czech, 1991) . Considerable interest in CKII has arisen in the past few years because it has been reported to be activated in response to mitogens including serum (Carroll & Marshak, 1989) , the tumour promoter 12-O-tetradecanoylphorbol 13-acetate (TPA; Carroll et al., 1988) , insulin (Sommercorn et al., 1987; Klarlund & Czech, 1988) , insulin-like growth factor I (Klarlund & Czech, 1988) Osheroff, 1989). CKII has a broad substrate specificity and targets many nuclear proteins which have been implicated in growth control, some of which are discussed below.] CREB is phosphorylated by other known protein kinases in vitro and may therefore be a target for other signalling pathways. PKC phosphorylates Ser-133 (which is also phosphorylated by PKA) and two other as-yet-unidentified sites in vitro . Phosphorylation by PKC (presumably at these other sites) increases binding of CREB to the CRE and stimulates formation of CREB homodimers . However, it is not yet clear whether CREB and PKC interact in vivo. Evidence to date suggests that TPA treatment of cells does not elicit a CRE-dependent stimulation of gene expression Sheng et al., 1991; Hoeffier et al., 1989; Karmer et al., 1991) , suggesting that PKC does not play a role, at least directly, in CREB-dependent activation of transcription.
Ca2+ mediates gene induction in response to membrane depolarization of various neuronal cell lines and this inducibility has been mapped to CRE-like elements in different promoters (Sheng et al., 1988; Nguyen et al., 1990) . In addition, rapid phosphorylation of CREB at has been demonstrated in response to membrane stimulation (Sheng et al., 1991) (Sheng et al., 1991; Dash et al., 1991) . However, it is not yet known whether these kinases are the physiological mediators.
Further evidence of a role for CREB in cross-talk between signal transducing pathways comes from the effects of transforming growth factor ,/1 (TGF,f1) on gene expression in mink lung cells (Kramer et al., 1991) . TGF,/1 mediates its effects through the TRE and not the CRE (de Groot & Kruijer, 1990) and does not affect the intracellular level of cAMP (Kramer et al., 1991) . However, TGFfl1 (but not TPA) does induce phosphorylation of CREB and significantly stimulates the ability of this protein (as part of a heterodimer with a Fos-related protein) to interact with the TRE (Kramer et al., 1991) . CREB is therefore a target for phosphorylation (at an, as yet, unidentified site) by an, as yet, undefined cAMP-independent and TPAindependent signal, yet participates in transcriptional stimulation through an element normally associated with TPA responsiveness.
One final interesting aspect of the role of CREB phosphorylation in growth control and differentiation comes from studies of the loss of tissue-specific gene expression which occurs when different cell types are fused (Boshart et al., 1991; Jones et al., 1991) . This process of 'extinction' is thought to be mediated by trans-dominant regulatory factors. One such tissuespecific extinguisher of hepatocyte-specific genes, TSE1, represses transcription via the CRE and can be reversed by cAMPdependent stimulation of transcription (Boshart et al., 1991; Jones et al., 1991 , and references therein). TSE1 has recently been shown to encode the Rla regulatory subunit of PKA (Boshart et al., 1991; Jones et al., 1991 The products of the c-jun and c-fos proto-oncogenes are members of the AP-1 (activator protein-i) family of transcription factors which mediate transcriptional stimulation through their interaction with a specific DNA sequence (TGAC/GTCA; reviewed in Abate & Curran, 1990; Woodgett, 1990; Karin, 199 1a,b; Lewin, 1991 (Maki et al., 1987) . Its biochemical activity had already been strongly implied to be that of a transcription factor since it both bound the same DNA motif and showed structural similarity to the yeast transcriptional activator GCN4, particularly within the DNA binding region of this protein . Indeed the Jun and GCN4 DNA binding domains were shown to be functionally equivalent (Struhl, 1987) . The similarity between v-jun and its cellular counterpart (in chicken) c-jun is about 80 %; the differences are that v-Jun lacks an N-terminal region of 27 contiguous amino acids (termed the delta domain), and has two missense changes (D. Gillespie, personal communication) within its C-terminal region (there were originally thought to be three changes). The v-Jun protein is more highly transforming and a stronger transactivator than c-Jun, which has been attributed mainly to the absence from v-Jun of the delta domain ( Fig. 3a ; Baichwal & Tijan, 1990; Bos et al., 1990) .
Although there is a direct interaction between PKA and CREB in the cyclic AMP signalling pathway, there is no such direct interaction between PKC and c-Jun in the TPA-stimulated pathway. Rather, TPA treatment of cells induces rapid dephosphorylation of Jun at a specific site(s) which lies very close to the DNA binding domain (Boyle et al., 1991) . This region contains three residues, Thr-239 and Ser-243 and -249, which are phosphorylated in vivo and can be phosphorylated in vitro by glycogen synthase kinase 3 (GSK3; Boyle et al., 1991) . [GSK3 is a kinase which was originally associated with glycogen metabolism, but is now thought to play a major role in growth control and development (Woodgett, 1991) .] Phosphorylation of a bacterially expressed Jun protein by GSK3 blocks the ability of Jun to interact with the TRE, suggesting that phosphorylation may regulate DNA binding in vivo (Boyle et al., 1991) . [Another kinase reported to phosphorylate this site in vitro is the ERT (epidermal growth factor receptor threonine) kinase ), but it is not known which kinase phosphorylates these sites in vivo.] It is interesting that mutation of Ser-243 to phenylalanine (a change naturally occurring in the v-Jun protein) prevents phosphorylation of all three C-terminal sites in vivo and promotes AP-1 activity by about 10-fold (Boyle et al., 1991 Activation of Jun in response to TPA treatment may also be mediated partly through changes in phosphorylation of residues closer to the N-terminus. Phorbol ester treatment also induces phosphorylation of two N-terminal serine residues at positions 62 and 72 (Pulverer et al., 1991) . Jun proteins in which these residues have been mutated to encode leucine residues have impaired transactivation activity (Pulverer et al., 1991) suggesting the phosphorylation of these sites is required to activate Jun. Both of these residues lie within a proline-rich region required for transactivation and are substrates for phosphorylation in vitro by mitogen-activated protein kinases [Pulverer et al., 1991;  mitogen activated protein (MAP) Nuclear protein phosphorylation and growth control phosphorylated by MAP kinase(s) in vivo (Pulverer et al., 1991) . It is interesting that the Ha-ras oncogene, which has been shown to activate MAP-2 kinase (ERK2) through stimulation of PKC (Leevers & Marshall, 1992) , augments transactivation by Jun . Indeed, Ha-ras stimulates phosphorylation of Jun at the sites which are targetted by MAP kinase , while mutation of these sites abolishes the effect of Ras, indicating that phosphorylation is essential for stimulation . Activation of Jun by this mechanism is thought to play a major role in oncogene cooperativity between Ras and Jun.
It is important to stress the pivotal role played by MAP kinase in signal transduction (reviewed by Thomas, 1992) . [This family of kinases is known by several names, including mitogen activated protein (MAP) kinases, microtubule-associated protein-2 (MAP-2) kinases, myelin basic protein (MBP) kinases and extracellular signal-regulated protein kinases (ERKs). Individual members of the family characterized to date include p42maPk/erk2 p44maPk/erkl and p54maPk. In this review the MAP kinases will be referred to collectively as MAP kinase.] MAP kinase is activated by a number of external ligands [including nerve growth factor, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and insulin (Hoshi et al., 1988; Ray & Sturgill, 1988; Rossomando et al., 1989; Ahn et al., 1990; Gomez et al., 1990; Miyasaka et al., 1990; Boulton et al., 1991) ] which mediate their signals through tyrosine kinase receptors. These molecules trigger phosphorylation of multiple cellular proteins on tyrosine residues and activate a protein kinase cascade which leads to rapid phosphorylation and activation of MAP kinase. MAP kinase itself is phosphorylated by MAP kinase kinase which targets both a threonine and a tyrosine residue in the protein Gomez & Cohen, 1991 One additional interesting aspect of the N-terminal phosphorylation of Jun is the role of the delta domain which is located N-terminal to the MAP kinase phosphorylation sites (Fig. 3a) . In vivo, v-Jun, which lacks the delta region, is underphosphorylated (at N-terminal phosphorylation sites) when compared with c-Jun and experiments using hybrid v-Jun/c-Jun proteins have correlated this reduction in phosphorylation with the absence of the delta domain (Black et al., 1991 Curran, 1990; Woodgett, 1990; Karin, 1991a,b; Lewin, 1991 (Barber & Verma, 1987) . However, c-Fos is more extensively phosphorylated than v-Fos (by about 2-3-fold) and contains unique sites of phosphorylation which lie close to the C-terminus, within the 40-amino-acid region of c-Fos which is substituted by other sequences in the v-Fos protein (Barber & Verma, 1987 (Ofir et al., 1990) . In addition, mutation of residues 362-364 gives rise to a Fos protein which is activated for cellular transformation (Tratner et al., 1992) these kinases have been mapped (cdkl also phosphorylates the C-terminal transrepression domain), the specific residues which are phosphorylated are not known, nor is it yet certain whether these kinases phosphorylate physiological sites or affect Fos activity (Abate et al., 199 lb) . One particularly interesting observation is that Fos can be phosphorylated in vitro by doublestranded DNA-activated protein kinase (dsDNA-PK; LeesMiller & Anderson, 1991) . Indeed, Fos is the best substrate for dsDNA-PK so far identified . This large serine/threonine kinase (reviewed by Lees-Miller and Anderson, 1991) has a molecular mass of 350000, is potently activated by low amounts of double stranded DNA (Lees-Miller et al., 1990 ) and targets other nuclear proteins which are involved in transcription , including T antigen and p53 (see below). The physiological significance of phosphorylation of Fos by this kinase is unknown.
In summary, regulation of the transcription factor AP-1 by different mitogenic signals can occur through phosphorylation of both the Jun and Fos proteins. Future studies should extend our knowledge of the enzymes which target these proteins physiologically and the effects of covalent modulation on the interaction of the AP-1 transcription factor with both the transcriptional machinery and its DNA recognition element.
NF-KB
Nuclear factor kappa B (NF-KB) was originally identified as a transcriptional activator which mediates its effects through binding to an enhancer element (KB) within the K light chain immunoglobulin gene (reviewed by Baeuerle & Baltimore, 1991; Karin, 1991a (Sen & Baltimore, 1986) . Moreover, studies in vitro have shown that PKC phosphorylates the IKB component of the complex, leading to release of active NF-KB which is able to bind to DNA (Shirakawa & Mizel, 1989; Ghosh & Baltimore, 1990) . These findings form the basis for a model for NF-KB activation, in which the protein is sequestered in the cytoplasm as an inactive complex with lKB and released upon phosphorylation of the inhibitory subunit.
The free NF-KB heterodimer is then translocated into the nucleus where it binds to regulatory KB motifs and activates transcription.
Other signals may be mediated through phosphorylation of IKB. For example, haem-regulated eIF2 kinase (HRI) phosphorylates lKB and promotes dissociation of the NF-KB-IKB complex (Ghosh & Baltimore, 1990) . A similar mechanism may be involved in the activation of NF-KB by double-stranded RNA, which activates a kinase closely related to HRI (Ghosh & Baltimore, 1990) . NF-KB is also activated by interleukin-1 through a cAMP-dependent mechanism (Shirakawa & Mizel, 1989) . In this case the NF-KB-IKB complex is not a substrate for PKA, but phosphorylation of an as-yet-unidentified protein by PKA is thought to mediate activation (Ghosh & Baltimore, 1990; Shirakawa & Mizel, 1989 (Lech et al., 1988; ; (iii) Myc has sequence-specific DNA binding activity (Blackwell et al., 1990) (Fig. 4) . One of these, GSK3, phosphorylates Myc within the proline/glutamine-rich domain but little else is known about this interaction at present (Luscher & Eisenman, 1990a) . CKII multiply phosphorylates c-Myc in vitro at two distinct regions, corresponding to amino acids 240-262 and 342-357 in the human c-Myc (Fig. 4 ; Luscher et al., 1989) . [CKII has also been shown to phosphorylate similar sites on the N-Myc protein ]. These sites are also phosphorylated in vivo (Luscher et al., 1989) and lie, respectively, within an acidic central region (240-262), and a segment (342-357) flanking the basic DNA-binding domain (Fig. 4) Regions containing phosphorylation sites are expanded and the amino acid sequences given, together with the known enzymes which mediate the phosphorylation and dephosphorylation reactions.
function. Surprisingly, mutation of the Ser-347 and -348 phosphorylation sites, which map close to the DNA-binding region, does not affect the transforming activity of Myc when coexpressed with the Bcr-Abl tyrosine kinase oncogene in Rat-I cells (Street et al., 1990) . Transforming activity would therefore appear to be independent of phosphorylation of Ser-347 and -348. The functional significance ofphosphorylation at these sites is therefore still unresolved but may still be important for Myc function. The role of the CKII phosphorylation site within the acidic domain has not been established either, but may be important, since earlier studies had shown that deletion of this region from v-Myc led to a restriction of the types of cell which could be transformed (Ramsay et al., 1980; Ramsay & Hayman, 1982) . Interestingly, Max, the companion protein of Myc, is also phosphorylated by CKII Blackwood et al., 1992) , but in this case, phosphorylation abolishes the specific DNA-binding activity associated with the Max homodimeric complex but not the heterodimeric complex (Berberich & Cole, 1992) . MAP kinase [previously designated epidermal growth factor receptor threonine (ERT) kinase] has also been shown to phosphorylate Myc on Ser-62 both in vitro and in vivo Seth et al., 1991; Pelech & Sanghera, 1992) . No function has as yet been given to this site, but since it lies within a region which is required for transcriptional activation (Lech et al., 1988; and for the proposed association with the product of the retinoblastoma susceptibility gene (Rustgi et al., 1991) , its phosphorylation could regulate these associations. element (MRE; Biedenkapp et al., 1988) . Several regions, including the DNA binding and transactivation domains, have been mapped within both the v-and c-Myb proteins (Fig. 5) . In addition, c-Myb contains a C-terminal negative regulatory domain, deletion of which activates the transcriptional activation potential of the protein, and N-terminal sites which are modified by phosphorylation. Expression of Myb is restricted mainly to haematopoietic cells. Elevated expression of the protein can lead to stimulation of cell proliferation and inhibition of differentiation, suggesting that it may play a role in regulating the growth and differentiation of cells of haematopoetic lineage.
Myb is multiply phosphorylated in vivo at probably five sites (as defined by tryptic phosphopeptide mapping; Luscher et al., 1990) . Only two of these, Ser-1 1 and -12, have been identified to date . In vitro, Myb is an excellent substrate for CKII which targets both of these established in vivo Myb is a short-lived nuclear protein which is encoded by the proto-oncogene c-myb (for reviews, see Luscher & Eisenman, 1990b; Weston, 1990; Shen-Ong, 1990 (Luscher et al., 1990b) . Although separated from the DNA-binding domain by more than 50 residues, phosphorylation at these two residues potently down-regulates the ability of Myb to bind to its target sequence, the MRE, in vitro There is further evidence from oncogenic activation of Myb to support a role for and -12 in down-regulation of Myb activity in vivo. Firstly, the activated N-terminally truncated v-Myb proteins which are encoded by AMV and E26 lack the CKII phosphorylation sites (Weston & Bishop, 1989 . Further analysis of these phosphorylation sites, perhaps by site-directed mutagenesis, should confirm whether it is loss of phosphorylation per se, or loss of other Nterminal residues, which is the basis of unregulated DNA binding activity.
Little else is known about Myb phosphorylation at present. There are clearly other sites which are phosphorylated in vivo . One possible contender for targetting these sites in vivo is glycogen synthase kinase 3 (GSK3) which has already been discussed as a nuclear kinase with respect to its phosphorylation ofJun (see above). Three closely spaced residues in c-Myb are phosphorylated by GSK3 in vitro and a major Myb kinase co-purifies with GSK3, suggesting that it might target Myb in vivo (Woodgett, 1991) . Future studies should reveal the functional significance of this interaction and the signals which control the phosphorylation of Myb.
THE LARGE T ANTIGEN OF SV40
The large tumour antigen (T antigen) of simian virus 40 (SV40) is a 708-amino-acid protein which is expressed early after SV40 infection. This fascinating molecule encompasses, within a single polypeptide, a number of biochemical activities which are required for the initiation of viral DNA synthesis and the coordination of events in viral replication (Livingston & Bradley, 1987) . Viral propagation requires expression of the early region (including T antigen) which then permits replication of the viral genome and expression of the late region encoding the viral coat proteins. Replication activities include site-specific DNA binding, ATPase and DNA unwinding activities, all of which are essential for viral DNA replication. DNA binding occurs at two sites (termed sites I and II) at the viral origin of replication; binding to site I acts to repress transcription of the early region and augments viral DNA replication, whereas binding to site II is the first step in initiating viral DNA replication. In addition to transcriptional repression, T antigen is a transactivator of late transcription of viral genes. Complex formation of T antigen with two 'tumour suppressor' proteins, pRB (the product of the retinoblastoma susceptibility gene) and p53 (see below), is thought to stimulate the cell's replication machinery to accommodate SV40 replication, and is also thought to be (at least part of) the mechanism by which SV40 can cause cellular transformation.
T antigen is phosphorylated at multiple sites which are clustered into two clearly distinct domains (Kress et al., 1982; Scheidtmann et al., 1982 Scheidtmann et al., , 1991a Van Roy et al., 1983; see Fig.  6 ). At the N-terminus, phosphorylation occurs at Ser-106, 111, 1 2, 120, 123 and Thr-124. Residues 106-112 lie within a domain which is conserved among papovaviruses (Moran, 1988) and is involved in cellular transformation and complex formation with the pRB protein (DeCaprio et al., 1988) . adjacent to the nuclear localization signal (Kalderon et al., 1984) (Grasser et al., 1988; Fig. 6) which again implicates this enzyme in regulating growth. Casein kinase I phosphorylates Ser-123 in vitro (Grasser et al., 1988) . Phosphorylation at this residue may depend on prior phosphorylation at Ser-120 to generate a recognition determinant (Flotow et al., 1990; Scheidtmann et al., 199 la; Umpress et al., 1992) , but the kinase which phosphorylates Ser-120 is not known. Thr-124 is phosphorylated by the cell cycle-regulated kinase cdkl (p34cdc2) in vitro (McVey et al., 1989) and Ser-677 has recently been shown to be phosphorylated in vitro by dsDNA-PK (Lees-Miller et al., 1990; Chen et al., 1991) . Protein kinase activities which target other phosphorylation sites in T antigen have yet to be identified.
T antigen is an excellent example of a nuclear protein whose individual functions are regulated by separate phosphorylation events at different sites. The best-characterized effect of T antigen phosphorylation is its role in SV40 DNA replication (recently reviewed by Prives, 1990) , where a 'push-pull' mechanism of stimulatory and inhibitory phosphorylation events controls the activity of the protein. Early studies showed that removal of serine phosphates from T antigen stimulates initiation of DNA synthesis in vitro by several-fold (Mohr et al., 1987; Grasser et al., 1987) . This effect appears to be mediated solely by increased binding of T antigen to site II of the origin of replication (Simmons et al., 1986; Mohr et al., 1987; Klausing et al., 1988) . These studies suggested that phosphorylation of a serine residue(s) down-regulates origin-specific DNA binding and consequently the replication function of T antigen. Further evidence for control of replication by phosphorylation came from two different approaches. In the first, T antigen expressed in bacterial cells was shown to be inactive in replicating SV40 DNA in vitro (McVey et al., 1989) . However, when the bacterially expressed protein was phosphorylated at Thr-124 (by cdkl in vitro), it acquired a hyperactive role in replication (i.e. more active than T antigen from HeLa cells, which is phosphorylated at this and at other sites) and bound extremely efficiently to site II of the replication origin (McVey et al., 1989) . These findings indicated a positive role for phosphorylation of T antigen at Thr-124 and suggested that phosphorylation at another site(s) downregulates activity. Consistent with this idea, mutation of Thr-124 to alanine abolished the ability of T antigen to replicate SV40 DNA or produce viable virus particles, while mutation of Ser-679 enhanced replication by 5-fold and bound more tightly to site II than wild type T antigen (Schneider & Fanning, 1988) . Ser-679 may therefore mediate (at least in part) the inhibitory effect on replication highlighted by the phosphatase studies. Other sites have also been implicated in controlling replication by the finding that protein phosphatase 2A (PP2A) catalytic subunit [which is equivalent to the replication factor RP-C ] specifically dephosphorylates Ser-120, 123, 677 and 679, and activates DNA replication (Scheidtmann et al., 1991c; Lawson et al., 1990) . These studies also suggested a physiological role for PP2A in regulating T antigendependent replication. Moreover, G1 cell extracts promote SV40 DNA replication less efficiently than do S phase extracts (Roberts & D'Urso, 1988 ), but addition of PP2A to the G1 extract restores full activity . Based on these findings, it has been suggested that PP2A or a highly related phosphatase activity is regulated in a cell-cycle-dependent manner (Prives, 1990) . Concomitant activation of cdkl and PP2A at G1/S could therefore switch T antigen into an active replicating protein in a cell-cycle-dependent manner, thus allowing exploitation of the cell's replication machinery during S phase. It is also possible that the small t antigen of SV40, which down-regulates the activity of PP2A towards T antigen at the inhibitory phosphorylation sites (Yang et al., 1991; Scheidtmann et al., 1991b) , is necessary to maintain T antigen in an inactive replication state until its activation at an appropriate point in the cycle. Prior to S phase, T antigen may be employed in other function(s) such as transcription or tumour suppressor protein binding.
In addition to its effects on DNA replication, phosphorylation of T antigen may have profound effects on other biological and biochemical activities associated with this protein. For example, mutation of Ser-677 abolishes binding to site I in the origin (Schneider & Fanning, 1988) , and could therefore be involved in regulating repression of early SV40 transcription. However, although mutation of this site reduces viability of the virus slightly, there is not yet any direct evidence for a role in repression. Mutagenesis experiments have also shown that three residues are important for the transforming ability of T antigen. Loss of phosphorylation at Ser-639 causes a stimulation of cellular transformation (Schneider & Fanning, 1988; Scheidtmann et al., 1991a) , but the mechanism of this effect is not yet known. Phosphorylation of Ser-679 and especially Ser-677 are also thought to be important for transformation but in contrast to the loss of Ser-639, mutation of either of these sites gives rise to T antigen molecules which do not transform cells (Schneider & Fanning, 1988; Scheidtmann et al., 1991a) . Once again, both stimulatory and inhibitory phosphorylation events appear to control a function of T antigen. This result also suggests a role in transformation for dsDNA-PK which phosphorylates this site in vitro . The mechanism by which phosphorylation at this site influences transformation is not clear. However, phosphorylation of a mutant T antigen lacking Ser-677 is reduced at Ser-120 and -123 and enhanced at Ser-1 12 (Scheidtmann et al., 199 la), suggesting that modification of Ser-677 may influence the phosphorylation state of other regulatory sites. Further evidence for the involvement of these sites in transformation has come from a fascinating study describing Rev2, a cell line originally transformed by SV40, which has a revertant (non-transformed) phenotype (Deppert et al., 1991) . The T antigen expressed in this line is wild type and when rescued, retains the ability to fully transform other cell lines. Yet in the Rev2 background, expression of wild type T antigen is not transforming. Analysis of T antigen in Rev2 cells showed significant loss of phosphorylation at Ser-120, 123, 667 and 679 (Deppert et al., 1991) suggesting that phosphorylation at these sites may favour a transformation competent conformation of T antigen. The nature of the reversion is at present unknown, but it may inactivate a kinase(s) required for T antigen phosphorylation. It will be interesting to determine whether dsDNA-PK is active in these cells and whether expression of this kinase can restore transformation competence.
Another potentially interesting role for phosphorylation is in the transport of T antigen to the nucleus. Although nuclear localization is dependent on a specific sequence of amino acids (residues 126-132; Kalderon et al., 1984) , the rate of transport is influenced by residues 111-125 (Rihs & Peters, 1989) which contains several phosphorylation sites. Subsequent work has identified the casein kinase II site (Ser-112) as the determining factor for rapid nuclear transport (Rihs et al., 1991) and defined a biological role for phosphorylation of this residue.
Finally, although considerable progress has been made in understanding how the replication and transformation functions of T antigen are controlled, there are still many questions to be answered. The phosphorylation requirements for other activities Vol. 287 9 D. W. Meek and A. J. Street such as transcriptional activation, repression and binding to the pRB and p53 suppressor proteins are still unknown and it is therefore possible that phosphorylation at specific sites plays a major role in controlling individual functions.
pRB
The retinoblastoma susceptibility gene (RB) was originally identified as the genetic locus for predisposition to retinoblastoma (reviewed in Weinberg, 1990) . Mutation or deletion of both alleles of RB occurs in most retinoblastomas and in several other types of human cancer, indicating that loss of RB function is a major event in the pathogenesis of many forms of this disease . Reintroduction of the RB gene into cells which lack a functional RB has been shown to suppress several neoplastic phenotypes and abolish tumorigenic growth in nude mice Bookstein et al., 1990) . RB has therefore been classed as a tumour suppressor gene, the normal function of which is to negatively regulate cellular proliferation. The product of the RB gene (pRB) is a nuclear protein of molecular mass 110000 (Friend et al., 1986; Lee et al., 1987a,b; Fung et al., 1987) which is multiply phosphorylated Buchkovich et al., 1989) . The transforming proteins of several DNA tumour viruses interact with pRB and are thought to block its suppressor function, thereby contributing to the mechanism of transformation by these viruses (DeCaprio et al., 1988; Whyte et al., 1988; Dyson et al., 1989) .
There first is that the SV40 large T antigen complexes exclusively with unphosphorylated pRB suggesting that unphosphorylated pRB is the active suppressor. The second is that pRB undergoes striking cell-cycle-dependent changes in its phosphorylation state (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989; Xuet al., 1989; Ludlow et al., 1990; Furukawa et al., 1990a) , being predominantly unphosphorylated during the G1 phase of the cell cycle [where control of cell proliferation often occurs (Pardee, 1989) ], but hyperphosphorylated throughout S and G2/M (Fig. 7) . The occurrence of a major phosphorylation event at the G1/S boundary suggests that phosphorylation of pRB might signal commitment to continuation of the cell cycle either by promoting the onset of S phase or determining whether postmitotic cells enter the Go (quiescent) state or re-enter G1 (Cooper & Whyte, 1989) . This idea is consistent with the conclusion that T antigen targets only the active (unphosphorylated) species of pRB which is present at G1 and explains the ability of viral oncoproteins to stimulate cellular DNA synthesis and block differentiation.
There are several lines of evidence which support the idea that unphosphorylated pRB actively arrests cell growth. Firstly, pRB is rapidly dephosphorylated by agents which promote cellular differentiation or cell cycle arrest (Akiyama & Toyoshima, 1990; Chen et al., 1989; Mihara et al., 1989) , including physiological growth inhibitors such asa-interferon(oc-IFN) (Thomas et al., 1991) and transforming growth factor,/1 (TGF#1) (Laiho et al., 1990 ). Interestingly, TGFfl1 does not arrest cells which express T antigen, presumably because T antigen binds unphosphorylated pRB. However, in these cells, TGFfl1 retains the ability to block pRB phosphorylation (Laiho et al., 1990 ). This observation indicates that inhibition of pRB phosphorylation is not a consequence of growth arrest, but favours the idea that dephosphorylation of pRB is a key step in the mechanism which brings about growth arrest. A second line of evidence is that terminally differentiated or senescent cells cannot enter S phase following mitogenic stimulation and are unable to phosphorylate pRB (Furukawa etal., 1990a; Stein etal., 1990) , even although they undergo the same prereplicative events as stimulated quiescent cells (Stein etal., 1990) . This suggests that phosphorylation of pRB is required to re-enter the cell cycle. Finally, microinjection of unphosphorylated pRB directly arrests cell cycle progression in mid-G, phase; this block can be alleviated by T antigen (Goodrich etal., 1991) . Taken together, these findings suggest that dephosphorylation of pRB is an integral part of the mechanism of growth arrest.
The functional consequences of pRB phosphorylation at the molecular level are still unclear, but several recent studies have begun to address this question. At least seven cellular proteins can complex with pRB in vitro (Kaelin etal., 1991; Huang etal., 1991) , including the transcription factors c-Myc (Rustgi et al., 1991) and E2F (Bandara & La Thangue, 1991; Chellappan et al., 1991; Bagchi et al., 1991; Chittenden et al., 1991) . pRB is therefore thought to act as a transcriptional repressor by sequestering key proteins which are required for cell cycle progression (Wagner & Green, 1991) . Complex formation with E2F occurs only with unphosphorylated pRB and is restricted to G1 (Chellappan et al., 1991) . Others have shown that unphosphorylated pRB is tightly associated with subnuclear structures and is released from these complexes in late G1 or early S, coincident with the major pRB phosphorylation event (Mittnacht & Weinberg, 1991) . Based on these studies, it is likely that phosphorylation of pRB at a specific control point in G1 (or complex formation with oncoproteins) dissociates these subnuclear structures and, by releasing the sequestered proteins, allows the cell cycle to continue.
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Nuclear protein phosphorylation and growth control
The amino acid residues which are phosphorylated in pRB in vivo have not yet been rigorously identified, although peptide mapping has revealed that the protein contains more than 20 tryptic phosphopeptides . A large subset of these phosphopeptides are also present in pRB which has been phosphorylated in vitro by cdkl (p34cdc2), suggesting that this kinase is able to phosphorylate the physiological targets within the pRB sequence (Taya et al., 1989; Lin et al., 1991; . [Several consensus sequences for recognition by this kinase are present in pRB, and synthetic peptides corresponding to these sequences have been used to identify some of the sites phosphorylated in vitro (Taya et al., 1989; .] Immunodepletion of cdkl kinase from cell extracts (Lin et al., 1991) or expression of anti-cdkl oligonucleotides (Furukawa et al., 1990b) depletes the kinase activity towards pRB, suggesting that cdkl or a highly related kinase phosphorylates pRB in vivo.
In addition, other protein kinases are also likely to be active towards pRB in vivo. For example, partially phosphorylated species of pRB have been observed in early G1 prior to the major phosphorylation event at G1/S (Chen et al., 1989; Thomas et al., 1990; Fukurawa et al., 1990b) . Moreover, TGF,f1 can only partially block pRB phosphorylation, suggesting that there may be at least two pRB kinases, only one of which is responsive to TGF/31 (Laiho et al., 1990) . The identities of other kinase(s) which phosphorylate pRB are still unknown. Future studies should reveal the nature of these as well as clarify the biological roles of the differentially phosphorylated forms of pRB.
p53
The p53 tumour suppressor protein (Lane & Benchimol, 1990; Levine et al., 1991 ) is a fascinating nuclear phosphoprotein which can potently suppress cellular transformation (Finlay et al., 1989; Mercer et al., 1990; Eliyahu et al., 1989; Michalovitz et al., 1990) , inhibit tumorigenesis , arrest cell growth Diller et al., 1990 ) and induce apoptotic cell death (Yonish-Rouach et al., 1991) . Loss of the ability of p53 to tightly regulate cell growth, through mutation, is the most common genetic alteration in most inherited and sporadic forms of human cancer (Levine et at., 1991) . The suppressor activity of p53 is also blocked by the products of viral oncogenes such as the SV40 large T antigen, the adenovirus El B 55K protein and the E6 protein of human papilloma virus (HPV) types 16 and 18 (Fukasawa et al., 1991; Scheffner et al., 1990) . The mechanism by which p53 regulates cell growth at the molecular level is still unknown. However, its ability to block SV40 DNA replication (Braithwaite et al., 1987; Wang et al., 1989; Sturtzbecher et al., 1988) and interact with proteins involved in DNA replication (Gannon & Lane, 1987; Wilcock & Lane, 1991) have suggested that it might normally regulate the initiation of cellular DNA replication. Other studies have shown that p53 is a potent transcriptional activator (Raycroft et al., 1990; Fields & Jang, 1990; O'Rourke etal., 1990) . p53 may therefore have a dual role in regulating cell growth. Understanding its mechanism of action and regulation is a major goal in cancer biology. p53 is multiply phosphorylated by several different protein kinases (Fig. 8 ) and might therefore be controlled, perhaps coordinately, by more than one signal. Phosphorylation of p53 is also modulated by the transforming proteins of DNA tumour viruses, which suggests that it may play a central role in controlling the growth of the cell. There are two C-terminal phosphorylation sites in p53, Ser-309 and -386 (in mouse p53) and a cluster ofphosphorylation sites at the N-terminus, including Ser-4, 6, 15 and 34 (Samad et al., 1986; Meek & Eckhart, 1988) . Different cell lines or species show similar but not identical phosphorylation patterns and additional, as yet unidentified, sites of phosphorylation may be present.
There has been considerable progress in identifying the protein kinases which phosphorylate p53. Ser-315 in human p53 (equivalent to Ser-309 in mouse p53) is phosphorylated in vitro by the cdkl (p34`dc2) kinase (Bischoff et al., 1990; Addison et al., 1990) , suggesting that cell-cycle-dependent phosphorylation might control p53, perhaps as a fine tuning mechanism, in addition to the cell-cycle-regulated expression of p53 (Reich & Levine, 1984) . Evidence that p53 becomes more highly phosphorylated upon entering the S phase of the cell cycle supports this idea (Bischoff et al., 1990) . Moreover, since immunodepletion of cdkl from cell lysates removes the kinase activity which phosphorylates Ser-315 (Bischoff et al., 1990) , cdkl or a highly related kinase may well phosphorylate p53 in vivo. Whether this phosphorylation event regulates p53 function has not been established. Mutation of p53 at the cdc2 phosphorylation site in mouse p53 (Ser-309) has no effect on the ability of p53 to block replication of SV40 DNA in COS cells . However, some other activity such as growth suppression, transcriptional activation or perhaps nuclear localization (Addison et al., 1990; Dang & Lee, 1989) may be regulated by this phosphorylation event. The finding that transformation by SV40 increases phosphorylation at this site would suggest that it does play an important role (Meek & Eckhart, 1988) .
_4
A second growth-related kinase, CKII, phosphorylates p53 in vitro at Ser-386 Herrmann et al., 1991) . Two lines of evidence, the association of p53 with CKII (or a CKIIlike kinase) in p53 immunoprecipitates, and the co-purification of CKII with a p53 kinase from SV3T3 cells, support the idea that p53 is phosphorylated by CKII in vivo Herrmann et al., 1991) . Ser-386 is also the proposed site of attachment of an unusual RNA moiety (Samad & Carroll, 1991) , but the nature of this RNA or its physiological significance are far from clear at present. Recent evidence suggests that phosphorylation at Ser-386 is required for activating p53 suppressor function since replacement of the serine with an alanine residue abolishes the ability of p53 to suppress growth (Milne et al., 1992b) . Placing a constitutive negative charge at this site (aspartate) partially restores suppressor activity, suggesting that it is able to mimic phosphorylation (Milne et al., 1992b) . It is not yet known whether any physiological signals or conditions of growth are able to modulate the phosphorylation of p53 at this site and hence regulate its effects on cell growth.
Two kinases phosphor-ylate p53 at N-terminal sites. One of these is the dsDNA-PK which phosphorylates an as-yetunidentified serine residue(s) (Lees-Miller et al., 1990) . It is not yet known how this phosphorylation event may control p53 activity. Interestingly, p53 has been reported to be induced by DNA damage (Maltzman & Czyzyk, 1984) ; activation of dsDNA-PK by changes in the DNA structure could therefore mediate this signal. Such a mechanism could play a major role in the response of p53 to DNA damage preceding neoplastic transformation. Casein kinase I has also been shown to phosphorylate p53 at three Nterminal sites (Ser-4, 6 and 9; Milne et al., 1992a) . This is a monomeric serine/threonine kinase of molecular mass 37000, which is ubiquitous in eukaryotic cells and exists in both cytoplasmic and nuclear forms. A similar kinase, which is preferentially active towards p53, is present in SV3T3 cell lysates and has all the hallmarks of a CKI-related protein [four isoforms of casein kinase I have recently been identified by molecular cloning (Rowles et al., 1991) ]. Interestingly, a DNA repairdefective mutation (hrr25-1) in Saccharomyces cerevisiae lies within a gene encoding a protein kinase with striking similarity to CKI (Hoekstra et al., 1991 (Sturzbecher et al., 1987) . These changes may reflect increased phosphorylation only at a specific site or sites (Samad et al., 1986; Meek & Eckhart, 1988) . In this respect, a recent study by Scheidtmann's group is particularly interesting. Analysis of SV40-transformed and untransformed rat cell lines revealed the presence of a novel, as yet unidentified, phosphorylation site present only in the transformed cells (Scheidtmann & Haber, 1990 ). This novel phosphorylation, which resulted in the stoichiometric shift of p53 to a fastermigrating form, was dependent on protein synthesis and suggested that T antigen may induce a cellular kinase(s). Similar observations have been made by others (Sturzbecher et al., 1987) . Of additional interest is the finding that the SV40 small t antigen may promote phosphorylation of p53 by blocking protein phosphatase 2A-dependent dephosphorylation of p53 (Scheidtmann et al., 1991b) . Taken (Meisner & Czech, 1991 Nuclear protein phosphorylation and growth control Answers to these questions will undoubtedly provide a better understanding about key areas of growth control such as differentiation, development and cellular transformation.
